Naratuximab emtansine/rituximab yields promising responses in DLBCL

Data from an open-label, phase 2 study—presented during the 2021 American Society of Hematology Annual Meeting—suggests that naratuximab emtansine plus rituximab is well tolerated and effective among patients with relapsed/refractory DLBCL ineligible for stem cell transplant or CAR T-cell therapy. Overall response rate among this cohort was 44.7%, and those who responded to treatment reported a clinically meaningful improvement of 3 points (SD 6.6) on the lymphoma subscale of the FACT-Lym QoL.